267 related articles for article (PubMed ID: 25499044)
1. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.
Ventura J; Subotnik KL; Gitlin MJ; Gretchen-Doorly D; Ered A; Villa KF; Hellemann GS; Nuechterlein KH
Schizophr Res; 2015 Feb; 161(2-3):407-13. PubMed ID: 25499044
[TBL] [Abstract][Full Text] [Related]
2. Relationship between clinical improvement and functional gains with clozapine in schizophrenia.
Lee J; Takeuchi H; Fervaha G; Bhaloo A; Powell V; Remington G
Eur Neuropsychopharmacol; 2014 Oct; 24(10):1622-9. PubMed ID: 25156578
[TBL] [Abstract][Full Text] [Related]
3. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
4. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
[TBL] [Abstract][Full Text] [Related]
5. Remission after first-episode schizophrenia: results of a long-term follow-up.
Üçok A; Serbest S; Kandemir PE
Psychiatry Res; 2011 Aug; 189(1):33-7. PubMed ID: 21196051
[TBL] [Abstract][Full Text] [Related]
6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y, social function and long-term outcome in schizophrenia.
Stålberg G; Ekselius L; Lindström LH; Larhammar D; Bodén R
Schizophr Res; 2014 Jul; 156(2-3):223-7. PubMed ID: 24799298
[TBL] [Abstract][Full Text] [Related]
8. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study.
Amminger GP; Henry LP; Harrigan SM; Harris MG; Alvarez-Jimenez M; Herrman H; Jackson HJ; McGorry PD
Schizophr Res; 2011 Sep; 131(1-3):112-9. PubMed ID: 21741219
[TBL] [Abstract][Full Text] [Related]
9. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT
Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
11. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study.
Bergh S; Hjorthøj C; Sørensen HJ; Fagerlund B; Austin S; Secher RG; Jepsen JR; Nordentoft M
Schizophr Res; 2016 Aug; 175(1-3):57-63. PubMed ID: 27050475
[TBL] [Abstract][Full Text] [Related]
12. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
13. Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study.
Üçok A; Ergül C
Schizophr Res; 2014 Sep; 158(1-3):241-6. PubMed ID: 25107850
[TBL] [Abstract][Full Text] [Related]
14. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
15. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.
Milev P; Ho BC; Arndt S; Andreasen NC
Am J Psychiatry; 2005 Mar; 162(3):495-506. PubMed ID: 15741466
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
19. Posthospital course and outcome in schizophrenia.
Carone BJ; Harrow M; Westermeyer JF
Arch Gen Psychiatry; 1991 Mar; 48(3):247-53. PubMed ID: 1671742
[TBL] [Abstract][Full Text] [Related]
20. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.
Lambert M; Naber D; Schacht A; Wagner T; Hundemer HP; Karow A; Huber CG; Suarez D; Haro JM; Novick D; Dittmann RW; Schimmelmann BG
Acta Psychiatr Scand; 2008 Sep; 118(3):220-9. PubMed ID: 18699954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
